TY - STD TI - Cancer Research UK. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma. Accessed 21 Feb 2018. UR - http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma ID - ref1 ER - TY - JOUR AU - Kouroukis, T. C. PY - 2014 DA - 2014// TI - Bortezomib in multiple myeloma: systematic review and clinical considerations JO - Curr Oncol VL - 21 UR - https://doi.org/10.3747/co.21.1798 DO - 10.3747/co.21.1798 ID - Kouroukis2014 ER - TY - JOUR AU - Richardson, P. G. PY - 2014 DA - 2014// TI - Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-01-548826 DO - 10.1182/blood-2014-01-548826 ID - Richardson2014 ER - TY - JOUR AU - Chauhan, D. PY - 2011 DA - 2011// TI - In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-11-0476 DO - 10.1158/1078-0432.CCR-11-0476 ID - Chauhan2011 ER - TY - JOUR AU - Kumar, S. K. PY - 2014 DA - 2014// TI - Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-01-548941 DO - 10.1182/blood-2014-01-548941 ID - Kumar2014 ER - TY - JOUR AU - Nooka, A. K. PY - 2015 DA - 2015// TI - Treatment options for relapsed and refractory multiple myeloma JO - Blood VL - 125 UR - https://doi.org/10.1182/blood-2014-11-568923 DO - 10.1182/blood-2014-11-568923 ID - Nooka2015 ER - TY - JOUR AU - Brown, S. R. PY - 2017 DA - 2017// TI - Experiences of establishing an academic early phase clinical trials unit JO - Clinical Trials VL - 14 UR - https://doi.org/10.1177/1740774517710250 DO - 10.1177/1740774517710250 ID - Brown2017 ER - TY - JOUR AU - Richardson, P. G. PY - 2005 DA - 2005// TI - Bortezomib or high-dose dexamethasone for relapsed multiple myeloma JO - N Engl J Med VL - 352 UR - https://doi.org/10.1056/NEJMoa043445 DO - 10.1056/NEJMoa043445 ID - Richardson2005 ER - TY - JOUR AU - Kortuem, K. M. AU - Stewart, A. K. PY - 2013 DA - 2013// TI - Carfilzomib JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2012-10-459883 DO - 10.1182/blood-2012-10-459883 ID - Kortuem2013 ER - TY - JOUR AU - Dimopoulos, M. A. PY - 2012 DA - 2012// TI - Pomalidomide in combination with low-dose dexamethasone: demonstrates a asignificant progression free survival and overall survival advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study JO - Blood VL - 120 UR - https://doi.org/10.1182/blood.V120.21.LBA-6.LBA-6 DO - 10.1182/blood.V120.21.LBA-6.LBA-6 ID - Dimopoulos2012 ER - TY - JOUR AU - Lacy, M. Q. PY - 2011 DA - 2011// TI - Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-04-348896 DO - 10.1182/blood-2011-04-348896 ID - Lacy2011 ER - TY - JOUR AU - Leleu, X. PY - 2013 DA - 2013// TI - Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe xrjrncophone du Myélome 2009-02 JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2012-09-452375 DO - 10.1182/blood-2012-09-452375 ID - Leleu2013 ER - TY - JOUR AU - Damaj, G. PY - 2013 DA - 2013// TI - Results from a prospective, open-label, phase II trial of Bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.43.7285 DO - 10.1200/JCO.2012.43.7285 ID - Damaj2013 ER - TY - JOUR AU - O'Brien, P. C. AU - Fleming, T. R. PY - 1979 DA - 1979// TI - A multiple testing procedure for clinical trials JO - Biometrics VL - 35 UR - https://doi.org/10.2307/2530245 DO - 10.2307/2530245 ID - O'Brien1979 ER - TY - JOUR AU - Lin, D. Y. AU - Wei, L. J. AU - Ying, Z. PY - 1993 DA - 1993// TI - Checking the cox model with cumulative sums of martingale-based residuals JO - Biometrika VL - 80 UR - https://doi.org/10.1093/biomet/80.3.557 DO - 10.1093/biomet/80.3.557 ID - Lin1993 ER - TY - JOUR AU - Charlson, M. E. PY - 1987 DA - 1987// TI - A new method of classifying prognostic comorbidity in longitudinal studies: development and validation JO - J Chronic Dis VL - 40 UR - https://doi.org/10.1016/0021-9681(87)90171-8 DO - 10.1016/0021-9681(87)90171-8 ID - Charlson1987 ER - TY - JOUR AU - Moreau, P. PY - 2014 DA - 2014// TI - Oral therapy for multiple myeloma: ixazomib arriving soon JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-06-581611 DO - 10.1182/blood-2014-06-581611 ID - Moreau2014 ER - TY - JOUR AU - Kumar, S. PY - 2016 DA - 2016// TI - Phase 2 study of the all-Oral combination of Ixazomib plus cyclophosphamide and low-dose dexamethasone (ICd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM) JO - Blood VL - 128 UR - https://doi.org/10.1182/blood.V128.22.3327.3327 DO - 10.1182/blood.V128.22.3327.3327 ID - Kumar2016 ER -